Buprenorphine Induction for High Potency Synthetic Opioid Users
ORN Webinar Series: Presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO)
- Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder
- Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
- Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl
John J. Mariani, MD
Dr. John Mariani is an Associate Professor of Clinical Psychiatry at the Columbia University Irving Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) of Columbia University Irving Medical Center, which is a facility for conducting substance use disorder pharmacotherapy research. Dr. Mariani maintains a busy private practice in Manhattan and is the Medical Advisor to the Major League Baseball Players Association.
Julie Kmiec, DO, FAOAAM (Moderator)
Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.
Planner & Moderator for this webinar.
HPSO are the leading cause of overdose death in the US and minimal empiric data exist to guide treatment decisions. Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.
This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.
Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 AOA Category 1-A
This course is offered through The American Osteopathic Academy of Addiction Medicine.
To take this course you will be redirected to The American Osteopathic Academy of Addiction Medicine's website. You must login or create an account with The American Osteopathic Academy of Addiction Medicine in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch